文摘

Purpose The purpose of the study is to investigate the efficacy of an alpha-1 adrenergic receptor antagonist (silodosin) for the treatment of lower urinary tract symptoms (LUTS) associated with interstitial 125I implantation for prostate cancer. Methods This randomized single-center study involved 105 patients (53 with and 52 without silodosin). Silodosin was postoperatively administered, daily, for 6?months (8?mg/day). Urinary symptoms and pressure flow were evaluated preoperatively and postoperatively at 1, 3, 6, and 12?months. Results At 12?months, interstitial 125I implantation had induced a significant decrease in prostate volume (28.3?±?11.1-0.5?±?8.1?g in the silodosin group and 26.1?±?9.7-7.7?±?4.9?g in the controls) and the prostate-specific antigen level (7.1?±?3.6-.4?±?1.7?ng/mL in the silodosin group and 8.1?±?4.3-.3?±?1.2?ng/mL in the controls). Significant improvements in the international prostate symptom voiding subscores at 6?months and quality of life at 3?months were observed in those receiving silodosin. The pressure flow studies demonstrated that silodosin had significantly enlarged the bladder capacity when the first non-voiding contraction was seen at 3 and 12?months (3M: 127.1?±?74.8 vs. 118.2?±?83.9?mL, p?=?0.001; 12M: 123.7?±?79.3 vs. 100.3?±?73.4?mL, p?=?0.01); however, there were no improvements in the bladder outlet obstruction index (BOOI) or urinary flow. Conclusions Silodosin temporarily improved LUTS, but did not improve the BOOI after 125I implantation in the prostate.